Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study

Scottish Melanoma Group; D A Cameron; M C Cornbleet; R M Mackie; J A Hunter; M Gore; B Hancock; J F Smyth

doi:10.1054/bjoc.2000.1623

Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study

Scottish Melanoma Group, D A Cameron, M C Cornbleet, R M Mackie, J A Hunter, M Gore, B Hancock, J F Smyth

Research output: Contribution to journal › Article › peer-review

Abstract / Description of output

In 1989, the Scottish melanoma group initiated a randomized trial, comparing observation alone with 6 months' therapy with low dose interferon (given subcutaneously 3 MU day-1, twice weekly), for patients with primary melanomas of at least 3 mm Breslow thickness, or with evidence of regional node involvement. The trial was closed in 1993 with only 95 eligible patients randomized. There were no toxic deaths, and no patient failed to complete the treatment for reasons of toxicity. 6 months' treatment with low-dose interferon- resulted in a statistically significant improved disease-free survival for up to 24 months after randomization (P

Original language	English
Pages (from-to)	1146-9
Number of pages	4
Journal	British Journal of Cancer
Volume	84
Issue number	9
DOIs	https://doi.org/10.1054/bjoc.2000.1623
Publication status	Published - 4 May 2001

Keywords / Materials (for Non-textual outputs)

Adult
Antineoplastic Agents
Chemotherapy, Adjuvant
Disease-Free Survival
Drug Administration Schedule
Humans
Injections, Subcutaneous
Interferon-alpha
Melanoma
Recombinant Proteins
Skin Neoplasms

Access to Document

10.1054/bjoc.2000.1623

Cite this

@article{b78fa46cc63443a5a92cdf4178ca16b6,

title = "Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study",

abstract = "In 1989, the Scottish melanoma group initiated a randomized trial, comparing observation alone with 6 months' therapy with low dose interferon (given subcutaneously 3 MU day-1, twice weekly), for patients with primary melanomas of at least 3 mm Breslow thickness, or with evidence of regional node involvement. The trial was closed in 1993 with only 95 eligible patients randomized. There were no toxic deaths, and no patient failed to complete the treatment for reasons of toxicity. 6 months' treatment with low-dose interferon- resulted in a statistically significant improved disease-free survival for up to 24 months after randomization (P",

keywords = "Adult, Antineoplastic Agents, Chemotherapy, Adjuvant, Disease-Free Survival, Drug Administration Schedule, Humans, Injections, Subcutaneous, Interferon-alpha, Melanoma, Recombinant Proteins, Skin Neoplasms",

author = "{Scottish Melanoma Group} and Cameron, {D A} and Cornbleet, {M C} and Mackie, {R M} and Hunter, {J A} and M Gore and B Hancock and Smyth, {J F}",

year = "2001",

month = may,

day = "4",

doi = "10.1054/bjoc.2000.1623",

language = "English",

volume = "84",

pages = "1146--9",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "9",

}

TY - JOUR

T1 - Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study

AU - Scottish Melanoma Group

AU - Cameron, D A

AU - Cornbleet, M C

AU - Mackie, R M

AU - Hunter, J A

AU - Gore, M

AU - Hancock, B

AU - Smyth, J F

PY - 2001/5/4

Y1 - 2001/5/4

N2 - In 1989, the Scottish melanoma group initiated a randomized trial, comparing observation alone with 6 months' therapy with low dose interferon (given subcutaneously 3 MU day-1, twice weekly), for patients with primary melanomas of at least 3 mm Breslow thickness, or with evidence of regional node involvement. The trial was closed in 1993 with only 95 eligible patients randomized. There were no toxic deaths, and no patient failed to complete the treatment for reasons of toxicity. 6 months' treatment with low-dose interferon- resulted in a statistically significant improved disease-free survival for up to 24 months after randomization (P

AB - In 1989, the Scottish melanoma group initiated a randomized trial, comparing observation alone with 6 months' therapy with low dose interferon (given subcutaneously 3 MU day-1, twice weekly), for patients with primary melanomas of at least 3 mm Breslow thickness, or with evidence of regional node involvement. The trial was closed in 1993 with only 95 eligible patients randomized. There were no toxic deaths, and no patient failed to complete the treatment for reasons of toxicity. 6 months' treatment with low-dose interferon- resulted in a statistically significant improved disease-free survival for up to 24 months after randomization (P

KW - Adult

KW - Antineoplastic Agents

KW - Chemotherapy, Adjuvant

KW - Disease-Free Survival

KW - Drug Administration Schedule

KW - Humans

KW - Injections, Subcutaneous

KW - Interferon-alpha

KW - Melanoma

KW - Recombinant Proteins

KW - Skin Neoplasms

U2 - 10.1054/bjoc.2000.1623

DO - 10.1054/bjoc.2000.1623

M3 - Article

C2 - 11379605

SN - 0007-0920

VL - 84

SP - 1146

EP - 1149

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 9

ER -

Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study

Abstract / Description of output

Keywords / Materials (for Non-textual outputs)

Access to Document

Fingerprint

Cite this